Data analysis, clinical biostatistics and more.
Company founded in
Percent employees with university degree
Our team members are experts in biostatistics. Beyond that, we are experienced in project work, working on different infrastructures and with complex processes.
Staburo Client Segments
- Biotech, Medical Device companies, etc.
Temporally and spatially flexible
Experienced in pharma processes
Check out our latest news!
Post event: Anything new for oncology? Lately, Basel Biometric Section and EFSPI organized a webinar "Estimands addendum is final: Anything new for oncology?". You can find the program, the slides, a recording of the entire event, and a document that answers questions...
Staburo @ Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology? We are very proud that Staburo's Managing Director Dr. Hannes Buchner will be a speaker and will talk about "Treatment switching: challenges, estimands, and estimators". All...
How to Avoid Overfitting, Precision Medicine in Action & Tumour Growth Modelling – three PSI contributions
Staburo's 2020 PSI contributions in webinar format on 26 May (15:00 – 17:15 CET) Since the 2020 PSI conference will unfortunately not take place, we decided to share our PSI contributions in an online live webinar with our colleagues. Staburo biostatisticians Nicole...